AcuCort appoints Carl Frisk as Strategic Alliance Manager

AcuCort has appointed Carl Frisk as Strategic Alliance Manager. In this role, he will be responsible for the company’s commercial partnerships and for further developing AcuCort’s partner network across its markets.

AcuCort is in a phase of expansion, with growth driven through partnerships with companies responsible for marketing and sales in their respective markets. Carl Frisk will have overall responsibility for further developing these partnerships, with a focus on strengthening market presence, driving sales growth and creating long-term value.

Carl Frisk has extensive experience in sales, marketing and business development within the pharmaceutical industry. He has previously held senior commercial roles at, among others, Unimedic Pharma, Sanofi and Grünenthal Sweden, with responsibility for sales and marketing across the Nordic market. Through these roles, he has gained extensive experience in developing markets, establishing partnerships and driving commercial growth.

– Carl Frisk has extensive experience in the pharmaceutical industry, an extensive network and in-depth knowledge of AcuCort. He will play an important role in further developing our partnerships and supporting increased sales in our markets, says Jonas Jönmark, CEO of AcuCort.

Carl Frisk comments:

–AcuCort has an attractive product and a clear international strategy. I see significant opportunities to further develop the company’s commercial presence together with our partners and contribute to increased sales in our markets.

For further information: 
Jonas Jönmark, CEO, AcuCort AB
Phone: 070 365 5400
E-mail: jonas.jonmark@acucort.se

About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland, where the product is also marketed. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.